Redmile Group’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-658,336
| Closed | -$988K | – | 81 |
|
|
2023
Q1 | $988K | Sell |
658,336
-73,043
| -10% | -$98.4K | 0.04% | 73 |
|
|
2022
Q4 | $731K | Sell |
731,379
-363,266
| -33% | -$490K | 0.03% | 67 |
|
|
2022
Q3 | $1.97M | Hold |
1,094,645
| – | – | 0.08% | 64 |
|
|
2022
Q2 | $3.17M | Hold |
1,094,645
| – | – | 0.12% | 64 |
|
|
2022
Q1 | $3.02M | Sell |
1,094,645
-251,413
| -19% | -$791K | 0.09% | 63 |
|
|
2021
Q4 | $6.27M | Sell |
1,346,058
-2,470,651
| -65% | -$15.4M | 0.14% | 63 |
|
|
2021
Q3 | $32.5M | Buy |
3,816,709
+580,900
| +18% | +$8.21M | 0.57% | 45 |
|
|
2021
Q2 | $53.1M | Sell |
3,235,809
-374,979
| -10% | -$7.57M | 0.79% | 39 |
|
|
2021
Q1 | $79.7M | Buy |
3,610,788
+777,900
| +27% | +$21.2M | 1.12% | 32 |
|
|
2020
Q4 | $87.6M | Buy |
2,832,888
+39,600
| +1% | +$1M | 1.06% | 31 |
|
|
2020
Q3 | $56.8M | Buy |
2,793,288
+1,028,100
| +58% | +$18.1M | 1.04% | 33 |
|
|
2020
Q2 | $27.1M | Sell |
1,765,188
-2,100
| -0.1% | -$24.2K | 0.5% | 52 |
|
|
2020
Q1 | $13.7M | Sell |
1,767,288
-31,900
| -2% | -$390K | 0.38% | 50 |
|
|
2019
Q4 | $25.7M | Buy |
1,799,188
+8,900
| +0.5% | +$138K | 0.61% | 43 |
|
|
2019
Q3 | $26.9M | Sell |
1,790,288
-8,928
| -0.5% | -$139K | 0.9% | 34 |
|
|
2019
Q2 | $25.7M | Sell |
1,799,216
-8,040
| -0.4% | -$128K | 0.73% | 42 |
|
|
2019
Q1 | $28.7M | Buy |
+1,807,256
| New | +$32.1M | 0.84% | 40 |
|
Redmile Group's TCRR Position: Q2 2023 in Review
Redmile Group sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 658,336 shares — an estimated $988K sold.
Redmile Group first reported a position in TCRR in Q1 2019 and held it in 17 quarters. The position peaked at $87.6M in Q4 2020. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.
- Redmile Group reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Redmile Group sold 658,336 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $988K.
- Redmile Group first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2019 and held it in 17 quarters.
- Redmile Group's TCR2 Therapeutics Inc. Common Stock position peaked at $87.6M in Q4 2020.
- 0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.
Based on Redmile Group's 13F filing for Q2 2023, filed 14 Aug 2023.